NeoGenomics Company Leadership

NeoGenomics Management Team Effectiveness

The company has Return on Asset of (0.0303) % which means that on every $100 spent on assets, it lost $0.0303. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1299) %, meaning that it generated no profit with money invested by stockholders. NeoGenomics' management efficiency ratios could be used to measure how well NeoGenomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of January 2026, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to grow to -0.08. At this time, NeoGenomics' Fixed Asset Turnover is very stable compared to the past year. As of the 11th of January 2026, Common Stock Shares Outstanding is likely to drop to about 15.5 M. In addition to that, Net Loss is likely to grow to about (123.3 M)The majority of NeoGenomics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NeoGenomics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NeoGenomics. Please pay attention to any change in the institutional holdings of NeoGenomics as this could imply that something significant has changed or is about to change at the company. Some institutional investors establish a significant position in stocks such as NeoGenomics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of NeoGenomics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

NeoGenomics Workforce Comparison

NeoGenomics Profit Margins

The company has Net Profit Margin of (0.16) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.08) %, which entails that for every $100 of revenue, it lost $0.08.

NeoGenomics Insider Trading History

NeoGenomics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as NeoGenomics often depends on how effective the management is. NeoGenomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NeoGenomics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NeoGenomics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.